GalNAc unconjugated/naked Fitusiran sodium（Cat No.:I041222）is an RNA interference (RNAi) therapeutic designed to target and inhibit the production of antithrombin, a protein involved in blood clotting regulation. Fitusiran works by reducing the synthesis of antithrombin in the liver, which can help manage bleeding disorders such as hemophilia, where clotting factor deficiencies are present. The GalNAc (N-acetylgalactosamine) conjugation typically facilitates targeted delivery to liver cells, but in its unconjugated or naked form, Fitusiran is less specifically targeted. It is under investigation for its potential to improve clotting factor activity in patients with bleeding disorders.
